Young children treated for eosinophilic esophagitis (EoE) with dupilumab (a biologic medication) were less likely to develop asthma in the future compared with children who received a different treatment.

Young children treated for eosinophilic esophagitis (EoE) with dupilumab were less likely to develop asthma in the future compared with children who received a different treatment. The findings come from ...